Cargando…
A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice
Dendritic cells (DCs), as professional antigen-presenting cells (APCs), play a key role in the initiation and regulation of humoral and cellular immunity. DC vaccines loaded with different tumor-associated antigens (TAAs) have been widely used to study their therapeutic effects on cancer. A number o...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325010/ https://www.ncbi.nlm.nih.gov/pubmed/35891256 http://dx.doi.org/10.3390/vaccines10071092 |
_version_ | 1784756943763537920 |
---|---|
author | Pan, Jiayi Zeng, Wuyi Jia, Jiangtao Shi, Yi Wang, Danni Dong, Jun Fang, Zixuan He, Jiashan Yang, Xinyu Zhang, Rong He, Menghua Huang, Maoping Fu, Bishi Zhong, Bei Liu, Hui |
author_facet | Pan, Jiayi Zeng, Wuyi Jia, Jiangtao Shi, Yi Wang, Danni Dong, Jun Fang, Zixuan He, Jiashan Yang, Xinyu Zhang, Rong He, Menghua Huang, Maoping Fu, Bishi Zhong, Bei Liu, Hui |
author_sort | Pan, Jiayi |
collection | PubMed |
description | Dendritic cells (DCs), as professional antigen-presenting cells (APCs), play a key role in the initiation and regulation of humoral and cellular immunity. DC vaccines loaded with different tumor-associated antigens (TAAs) have been widely used to study their therapeutic effects on cancer. A number of clinical trials have shown that DCs are safe as an antitumor vaccine and can activate certain anti-tumor immune responses; however, the overall clinical efficacy of DC vaccine is not satisfactory, so its efficacy needs to be enhanced. MUC1 is a TAA with great potential, and the immune checkpoint PD-L1 also has great potential for tumor treatment. Both of them are highly expressed on the surface of various tumors. In this study, we generated a novel therapeutic MUC1-Vax tumor vaccine based on the method of PD-L1-Vax vaccine we recently developed; this novel PD-L1-containing MUC1-Vax vaccine demonstrated an elevated persistent anti-PD-L1 antibody production and elicited a much stronger protective cytotoxic T lymphocyte (CTL) response in immunized mice. Furthermore, the MUC1-Vax vaccine exhibited a significant therapeutic anti-tumor effect, which significantly inhibited tumor growth by expressing a high MUC1(+) and PD-L1(+) level of LLC and Panc02 tumor cells, and prolonged the survival of cancer-bearing animals. Taken together, our study provides a new immunotherapy strategy for improving the cross-presentation ability of therapeutic vaccine, which may be applicable to pancreatic cancer, lung cancer and for targeting other types of solid tumors that highly express MUC1 and PD-L1. |
format | Online Article Text |
id | pubmed-9325010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93250102022-07-27 A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice Pan, Jiayi Zeng, Wuyi Jia, Jiangtao Shi, Yi Wang, Danni Dong, Jun Fang, Zixuan He, Jiashan Yang, Xinyu Zhang, Rong He, Menghua Huang, Maoping Fu, Bishi Zhong, Bei Liu, Hui Vaccines (Basel) Article Dendritic cells (DCs), as professional antigen-presenting cells (APCs), play a key role in the initiation and regulation of humoral and cellular immunity. DC vaccines loaded with different tumor-associated antigens (TAAs) have been widely used to study their therapeutic effects on cancer. A number of clinical trials have shown that DCs are safe as an antitumor vaccine and can activate certain anti-tumor immune responses; however, the overall clinical efficacy of DC vaccine is not satisfactory, so its efficacy needs to be enhanced. MUC1 is a TAA with great potential, and the immune checkpoint PD-L1 also has great potential for tumor treatment. Both of them are highly expressed on the surface of various tumors. In this study, we generated a novel therapeutic MUC1-Vax tumor vaccine based on the method of PD-L1-Vax vaccine we recently developed; this novel PD-L1-containing MUC1-Vax vaccine demonstrated an elevated persistent anti-PD-L1 antibody production and elicited a much stronger protective cytotoxic T lymphocyte (CTL) response in immunized mice. Furthermore, the MUC1-Vax vaccine exhibited a significant therapeutic anti-tumor effect, which significantly inhibited tumor growth by expressing a high MUC1(+) and PD-L1(+) level of LLC and Panc02 tumor cells, and prolonged the survival of cancer-bearing animals. Taken together, our study provides a new immunotherapy strategy for improving the cross-presentation ability of therapeutic vaccine, which may be applicable to pancreatic cancer, lung cancer and for targeting other types of solid tumors that highly express MUC1 and PD-L1. MDPI 2022-07-08 /pmc/articles/PMC9325010/ /pubmed/35891256 http://dx.doi.org/10.3390/vaccines10071092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pan, Jiayi Zeng, Wuyi Jia, Jiangtao Shi, Yi Wang, Danni Dong, Jun Fang, Zixuan He, Jiashan Yang, Xinyu Zhang, Rong He, Menghua Huang, Maoping Fu, Bishi Zhong, Bei Liu, Hui A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice |
title | A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice |
title_full | A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice |
title_fullStr | A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice |
title_full_unstemmed | A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice |
title_short | A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice |
title_sort | novel therapeutic tumor vaccine targeting muc1 in combination with pd-l1 elicits specific anti-tumor immunity in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325010/ https://www.ncbi.nlm.nih.gov/pubmed/35891256 http://dx.doi.org/10.3390/vaccines10071092 |
work_keys_str_mv | AT panjiayi anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT zengwuyi anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT jiajiangtao anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT shiyi anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT wangdanni anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT dongjun anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT fangzixuan anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT hejiashan anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT yangxinyu anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT zhangrong anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT hemenghua anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT huangmaoping anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT fubishi anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT zhongbei anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT liuhui anoveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT panjiayi noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT zengwuyi noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT jiajiangtao noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT shiyi noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT wangdanni noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT dongjun noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT fangzixuan noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT hejiashan noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT yangxinyu noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT zhangrong noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT hemenghua noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT huangmaoping noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT fubishi noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT zhongbei noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice AT liuhui noveltherapeutictumorvaccinetargetingmuc1incombinationwithpdl1elicitsspecificantitumorimmunityinmice |